Overview

Low Dose Aspirin for the Prevention of Preeclampsia

Status:
Unknown status
Trial end date:
2014-01-01
Target enrollment:
0
Participant gender:
Female
Summary
Preeclampsia is one of the three leading causes of maternal morbidity and mortality all over the world. The use of low dose aspirin has been mentioned in several studies with promising results. The investigators decided to evaluate the use of low dose aspirin, starting between 13 and 16 weeks of pregnancy, based on clinical characteristics only to reduce the incidence of preeclampsia.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Saint Thomas Hospital, Panama
Treatments:
Aspirin
Criteria
Inclusion Criteria:

- Gestational age between 13 and 16 weeks of pregnancy

- High risk of preeclampsia, based in clinical risk factors as:

Preeclampsia in a previous pregnancy Mother or sister that developed preeclampsia in a
previous pregnancy Diabetes Mellitus (insulin dependant) Chronic Hypertension (with/without
proteinuria) Body Mass Index > 32 Multiple pregnancy Lupus or other autoimmune disorder
Chronic Renal Disease.

Exclusion Criteria:

- Blood coagulation disorders of any kind

- Peptic ulcers

- Allergy to aspirin

- Chronic use of anti-inflammatory drugs

- Fetus with mayor anomalies